
    
      The objective of this study is to evaluate and compare the bioavailability of mesalamine and
      therefore to assess the bioequivalence of 375 mg APRISOTM extended-release capsule
      manufactured at a new site versus the approved 375 mg APRISOTM extended-release capsule after
      a single oral dose administration under fasting conditions.
    
  